ClinicalTrials.gg
RecruitingNCT07310056Updated Sep 9, 2026

The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms

An interventional study of Wearable-Based Digital Perioperative Rehabilitation System and Standard Perioperative Rehabilitation Guidance in Non-Small Cell Lung Cancer (NSCLC), Rehabilitation and Thoracic Surgery, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by West China Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital — 14 open to participants now, 14 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · West China Hospital.

Planned enrollment
6th of 15
126 · median 82
Started
2026
with 8 others
No phase
6 of 18
6 open now
Primary completion
2026-12
later than 3 of 13 live
Registered
11th of 18
by date

Among the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 9 that started in 2026, is one of 6 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital, or all of them as a file.
02

Study summary

This study aims to develop and evaluate an integrated perioperative management system based on wearable devices and a digital rehabilitation platform for patients with non-small cell lung cancer (NSCLC) undergoing thoracic surgery. By combining preoperative functional assessment using the six-minute walk test (6MWT), continuous perioperative physiological monitoring, and structured postoperative home-based digital rehabilitation, this randomized controlled trial will investigate whether the wearable-based digital management model improves short-term postoperative pulmonary function, functional recovery, and clinical outcomes compared with standard perioperative care.

Read the detailed description

With the rapid development of wearable sensor technology and digital health platforms, continuous physiological monitoring and remote rehabilitation have become feasible throughout the perioperative period. However, current perioperative management for lung cancer patients remains fragmented, with limited integration of preoperative functional assessment, intraoperative monitoring, and postoperative home-based rehabilitation. This study is designed to establish and validate a comprehensive wearable-based perioperative management system for patients with non-small cell lung cancer (NSCLC) undergoing surgical resection.

This study is a prospective, single-center, randomized, single-blind, superiority-controlled trial. A total of 126 eligible patients undergoing elective video-assisted thoracoscopic lobectomy or segmentectomy will be randomly assigned in a 1:1 ratio to either the intervention group or the control group. The control group will receive standard perioperative management and routine postoperative rehabilitation guidance. The intervention group will receive standard care plus a digital perioperative rehabilitation program supported by wearable devices and a remote monitoring platform.

During the preoperative phase, patients in the intervention group will undergo personalized prehabilitation including aerobic exercise training, respiratory muscle training, and resistance exercise. The six-minute walk test (6MWT), portable pulmonary function testing, and non-contrast functional lung MRI (PREFUL technology) will be performed for functional assessment. Wearable devices will continuously collect heart rate, blood oxygen saturation, step count, and activity level.

During the intraoperative phase, standardized surgical procedures and anesthetic management will be applied. Key intraoperative indicators including blood loss, ventilation time, anesthesia duration, and complications will be recorded through the anesthesia and surgical information systems.

During the postoperative phase, patients in the intervention group will receive 30-day home-based digital rehabilitation, including daily exercise tasks, real-time wearable data upload, electronic patient-reported outcomes (ePROs) reporting of symptoms (pain, fatigue, dyspnea), and remote review and guidance by medical staff via the digital platform. The control group will receive routine discharge education and outpatient follow-up.

The primary endpoint of the study is the between-group difference in pulmonary function (FEV₁) at 30 days and 3 months after surgery. Secondary endpoints include six-minute walk distance, peak oxygen consumption (VO₂ peak), postoperative complications, chest tube duration, length of hospital stay, time to first ambulation, 30-day readmission rate, analgesic consumption, symptom burden assessed using the MD Anderson Symptom Inventory-Lung Cancer module (MDASI-LC), and rehabilitation adherence based on platform usage data.

By integrating wearable-based continuous monitoring, objective functional assessment, and structured digital rehabilitation, this study aims to establish a closed-loop, data-driven perioperative management model. The results are expected to provide high-quality clinical evidence for the effectiveness, safety, and feasibility of wearable-assisted perioperative rehabilitation in lung cancer patients, and to promote the clinical translation of digital health technologies into thoracic surgery practice.

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
  • Rehabilitation
  • Thoracic Surgery
  • Perioperative Management

Keywords

  • Non-Small Cell Lung Cancer
  • Lung Cancer Surgery
  • Wearable Devices
  • Perioperative Management
  • Rehabilitation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤85 years
  • confirmed primary non-small cell lung cancer (NSCLC)
  • Scheduled to undergo elective curative-intent thoracoscopic lobectomy or segmentectomy
  • Able to independently operate a smartphone and wearable device, or able to do so with caregiver assistance
  • Willing to comply with study procedures and follow-up requirements
  • Provided written prior to participation

Exclusion criteria

Exclusion Criteria:

  • Preoperative long-term home oxygen therapy or severe resting respiratory failure
  • Presence of severe or uncontrolled cardiopulmonary disease, cerebrovascular disease, hepatic insufficiency, or renal insufficiency
  • Severe comorbid conditions that significantly limit physical activity or adherence to rehabilitation
  • Known or suspected allergy to materials used in wearable devices or medical adhesives
  • Any other condition that, in the judgment of the investigators, makes the participant unsuitable for study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Experimental

    Patients in this arm receive standard perioperative care plus a wearable-based digital perioperative rehabilitation program. The intervention includes preoperative personalized exercise training (aerobic exercise, respiratory muscle training, and resistance training), real-time six-minute walk test monitoring, portable pulmonary function testing, and continuous physiological monitoring using wearable devices (heart rate, oxygen saturation, and activity level). After discharge, patients undergo a 30-day home-based digital rehabilitation program with daily exercise tasks, real-time data upload, electronic patient-reported outcomes (ePROs), and remote guidance via a digital platform. Rehabilitation plans are dynamically adjusted based on patient performance and physiological data.

    Device: Wearable-Based Digital Perioperative Rehabilitation System

  • Active comparator
    Standard Perioperative Care

    Patients in this arm receive standard perioperative management only. This includes routine preoperative assessment, standardized surgical and anesthesia care, and conventional postoperative rehabilitation guidance at discharge. No wearable device monitoring, prehabilitation training, or digital home-based rehabilitation platform is provided. Patients are followed according to routine outpatient follow-up schedules after discharge.

    Behavioral: Standard Perioperative Rehabilitation Guidance

Interventions

  • DeviceWearable-Based Digital Perioperative Rehabilitation System

    This intervention consists of a wearable-based digital perioperative rehabilitation system designed for patients with non-small cell lung cancer undergoing thoracic surgery. The system integrates continuous physiological monitoring, functional assessment, and remote rehabilitation management. During the preoperative phase, patients receive personalized prehabilitation including aerobic exercise, respiratory muscle training, and resistance training. Wearable devices continuously monitor heart rate, oxygen saturation, activity level, and walking distance, including real-time monitoring during the six-minute walk test. Portable pulmonary function testing and functional MRI (PREFUL) are used for baseline assessment. During the postoperative phase, patients receive 30 days of home-based digital rehabilitation, including daily exercise tasks, real-time data upload, electronic patient-reported outcomes, and remote feedback from clinicians via a digital platform. Rehabilitation plans are dynam

  • BehavioralStandard Perioperative Rehabilitation Guidance

    This behavioral intervention consists of standard perioperative rehabilitation guidance provided to patients undergoing thoracic surgery for non-small cell lung cancer. Patients receive routine preoperative assessment, standardized postoperative discharge education, and conventional rehabilitation instructions including breathing exercises, early mobilization, pain management, and activity recommendations. No structured prehabilitation program, wearable device monitoring, remote digital platform, or continuous physiological monitoring is provided. Post-discharge follow-up is conducted according to routine outpatient clinical practice.

06

What researchers measure

Primary outcomes

  1. Time from return to the ward to first postoperative ambulation

    Time, measured in hours, from the patient's return to the surgical ward after surgery to the first postoperative out-of-bed ambulation. First ambulation is defined as the patient getting out of bed and standing or walking, with or without assistance.

    Time frame: From return to the surgical ward to first postoperative out-of-bed ambulation, censored at the date of hospital discharge, assessed up to the date of initial discharge (typically up to 14 days post-surgery).

Secondary outcomes

  1. Six-Minute Walk Distance (6MWD)

    The change in six-minute walk distance will be used to evaluate functional exercise capacity and recovery after surgery.

    Time frame: Baseline (preoperative), 30 days after surgery, and 3 months after surgery

  2. Change in Forced Expiratory Volume in 1 Second (FEV₁)

    Change in forced expiratory volume in 1 second (FEV₁), measured by spirometry, comparing postoperative pulmonary function recovery between the wearable-based digital rehabilitation group and the standard care group. Unit of Measure: Liters (L)

    Time frame: Baseline (preoperative), 30 days after surgery, and 3 months after surgery

  3. Change in Forced Vital Capacity (FVC)

    Change in forced vital capacity (FVC), measured by spirometry, comparing postoperative pulmonary function recovery between the wearable-based digital rehabilitation group and the standard care group.

    Time frame: Baseline (preoperative), 30 days after surgery, and 3 months after surgery

  4. Change in FEV₁/FVC Ratio

    Change in the ratio of forced expiratory volume in 1 second to forced vital capacity (FEV₁/FVC), measured by spirometry, comparing postoperative pulmonary function recovery between the wearable-based digital rehabilitation group and the standard care group.

    Time frame: Baseline (preoperative), 30 days after surgery, and 3 months after surgery

  5. Peak Oxygen Consumption (VO₂ peak)

    Peak oxygen consumption measured by cardiopulmonary exercise testing will be used to assess cardiorespiratory fitness.

    Time frame: 30 days and 3 months after surgery

  6. Postoperative Complication Rate

    The incidence of postoperative complications including pulmonary infection, atelectasis, prolonged air leak, pain, postoperative nausea and vomiting, and venous thromboembolism.

    Time frame: From surgery to 30 days after surgery

  7. Length of Postoperative Hospital Stay

    Total number of days of hospitalization after surgery.

    Time frame: From the date of surgery until the date of hospital discharge, assessed up to 90 days after surgery.

  8. Quality of Life (MDASI-LC)

    Quality of life and symptom burden will be assessed using the MD Anderson Symptom Inventory-Lung Cancer module (MDASI-LC), which evaluates pain, fatigue, dyspnea, sleep disturbance, and overall symptom severity in patients with lung cancer.

    Time frame: Baseline (preoperative), 30 days after surgery, and 3 months after surgery

  9. Patient satisfaction with postoperative monitoring

    Patient satisfaction with postoperative monitoring will be assessed using a study-specific questionnaire administered before hospital discharge. The questionnaire evaluates overall satisfaction, monitoring comfort, convenience during mobilization, sleep disturbance, perceived safety, monitoring-related discomfort, satisfaction with nursing care, and willingness to use the monitoring method again. Common items applicable to both groups will be rated using a 5-point Likert scale, ranging from 1 (very dissatisfied/strongly disagree) to 5 (very satisfied/strongly agree), with higher scores indicating greater satisfaction. Device-specific items will be analyzed descriptively in the wearable monitoring group only.

    Time frame: Within 24 hours before discharge from the index hospitalization

Other outcomes

  1. Regional Lung Function by Functional MRI (PREFUL)

    Regional ventilation and perfusion parameters evaluated by non-contrast functional MRI to assess postoperative regional lung function recovery.

    Time frame: Baseline (preoperative), 1 and 3 months after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 11 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 30, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07310056
Responsible party
Xuelei Ma MD (Department of Biotherapy, West China Hospital, Sichuan University, West China Hospital) — Principal investigator
First posted
Dec 30, 2025
Start date
Jan 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion